Daniel Bensimhon is a Cardiology physician affiliated with Cone Health. OpenAlex indexes 134 publications with 3,631 citations (h-index 34); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1200 N Elm St Ste 1982
Greensboro, NC 274011004
Telephone
336-832-9292Provider last certified this registry record 9 Aug 2024.
Clinical trials
- AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Sponsor: Peerbridge Health, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GE HEALTHCAREProgram year20258 payments$167,900openpaymentsdata.cms.gov ↗
- Bayer Healthcare Pharmaceuticals Inc.Program year202526 payments$33,673openpaymentsdata.cms.gov ↗
- Sensible Medical Innovations IncProgram year20251 payment$33,000openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.2%Beta blocker11.1%Carvedilol63%Metoprolol Succinate26%Bisoprolol Fumarate5%Metoprolol Tartrate3%Sotalol2%Propranolol Hcl2%Part D<11 patientsAngiotensin receptor-neprilysin inhibitor (ARNI)10.1%Entresto100%Part D≥167 patients+ 20 more classes in this area
Metabolism & gastrointestinal
15.6%SGLT2 inhibitor10.6%Jardiance54%Farxiga44%Dapagliflozin2%Part D≥113 patientsPotassium supplement3.5%Potassium Chloride75%Klor-Con M2025%Part D≥73 patients+ 2 more classes in this area
Blood & clotting
12.2%Factor Xa inhibitor8.1%Eliquis88%Xarelto12%Part D≥109 patientsVitamin K antagonist2%Warfarin Sodium100%Part D≥40 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Gary Sherrill, MD
Cone Health
Thomas Stuckey, MD
Cone Health
Murali Ramaswamy, MD, FAAFP
Cone Health
Cornelius Van Dam, MD
Cone Health
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”